Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in proportion of patients whose hearing is improved compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in final hearing threshold determined by PTA (a lower value represents… compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tympanic membrane perforation · sudden sensorineural hearing loss
1 finding from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
Intratympanic corticosteroids may leads to higher vertigo/dizziness: timing not reportedd compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
Intratympanic corticosteroids probably leads to higher ear pain: timing not reportedf compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Ear pain: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
Proportion of patients with resolution or improved symptoms at days 3 to 7 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
3 findings from 1 review
RR 1.33 [1.09, 1.62]
5 studies · 1043 participants
Moderate
RR 1.4 [1.08, 1.81]
4 studies · 869 participants
Low
RR 1.12 [0.87, 1.44]
1 study · 174 participants
Moderate
Proportion of patients with resolution or improved symptoms at days 4 to 14 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
2 findings from 1 review
Proportion of patients with resolution or improved symptoms at days 4 to 14 ‐ Co‐treatment with antibiotics · patients with acute sinusitis
Oral corticosteroids may leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (low certainty).
1 finding from 1 review
Adverse events · patients with acute sinusitis
1 finding from 1 review
Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Depot corticosteroids (systemic; 40 mg methylprednisolone IM every 3… showed no clear difference in mean number of oral ulcers compared with placebo (saline IM injection); GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review